Appellate Court Rules FDA Cannot Regulate Tobacco Products

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 9
Volume 7
Issue 9

WASHINGTON--A Federal appeals court has ruled that regulation of tobacco rests with Congress, not the FDA. In a 2-to-1 vote, a panel of the Fourth Circuit Court of Appeals, Richmond, Va, overturned a lower court ruling that had upheld FDA’s right to regulate tobacco.

WASHINGTON--A Federal appeals court has ruled that regulation of tobacco rests with Congress, not the FDA. In a 2-to-1 vote, a panel of the Fourth Circuit Court of Appeals, Richmond, Va, overturned a lower court ruling that had upheld FDA’s right to regulate tobacco.

The judges wrote, in the majority opinion: "We do not dispute in this case that Congress has charged the FDA with protecting the public health and that tobacco products present serious health risks for the public."

However, the judges went on to say, there is "strong evidence that Congress has reserved for itself the regulation of tobacco products rather than delegating that regulation to the FDA. . . . Based on our review of the record, the FDA lacks jurisdiction to regulate tobacco products, and all of the FDA’s regulations of tobacco products are invalid."

The proposed comprehensive tobacco bill, defeated in the Senate in June, would have explicitly granted FDA the right to regulate nicotine as a drug and cigarettes as a drug-delivery system.

The appellate court ruling overturns the FDA’s program to restrict teenage tobacco use that included requiring persons under age 27 to present photo ID when purchasing cigarettes and prohibiting the sale of tobacco products to persons under the age of 18.

Justice Department officials plan to appeal the ruling to the full Fourth Circuit appellate court. If the full court does not overturn the ruling of the three-judge panel, the government could then take its appeal to the US Supreme Court. The FDA’s antitobacco regulations will remain in effect during the appeals.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content